BIOMAT Database Logo BIOMAT Database Logo

Simultaneous solid organ, bone marrow, and islet allotransplantation in type I diabetic patients. 1994

P B Carroll, and P Fontes, and A S Rao, and C Ricordi, and H L Rilo, and A Zeevi, and M Trucco, and R Shapiro, and W B Rybka, and V Scantlebury
Pittsburgh Transplantation Institute, Pennsylvania.

UI MeSH Term Description Entries
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008297 Male Males
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D002096 C-Peptide The middle segment of proinsulin that is between the N-terminal B-chain and the C-terminal A-chain. It is a pancreatic peptide of about 31 residues, depending on the species. Upon proteolytic cleavage of proinsulin, equimolar INSULIN and C-peptide are released. C-peptide immunoassay has been used to assess pancreatic beta cell function in diabetic patients with circulating insulin antibodies or exogenous insulin. Half-life of C-peptide is 30 min, almost 8 times that of insulin. Proinsulin C-Peptide,C-Peptide, Proinsulin,Connecting Peptide,C Peptide,C Peptide, Proinsulin,Proinsulin C Peptide
D002678 Chimera An individual that contains cell populations derived from different zygotes. Hybrids,Chimeras,Hybrid
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic
D003922 Diabetes Mellitus, Type 1 A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence. Diabetes Mellitus, Brittle,Diabetes Mellitus, Insulin-Dependent,Diabetes Mellitus, Juvenile-Onset,Diabetes Mellitus, Ketosis-Prone,Diabetes Mellitus, Sudden-Onset,Diabetes, Autoimmune,IDDM,Autoimmune Diabetes,Diabetes Mellitus, Insulin-Dependent, 1,Diabetes Mellitus, Type I,Insulin-Dependent Diabetes Mellitus 1,Juvenile-Onset Diabetes,Type 1 Diabetes,Type 1 Diabetes Mellitus,Brittle Diabetes Mellitus,Diabetes Mellitus, Insulin Dependent,Diabetes Mellitus, Juvenile Onset,Diabetes Mellitus, Ketosis Prone,Diabetes Mellitus, Sudden Onset,Diabetes, Juvenile-Onset,Diabetes, Type 1,Insulin Dependent Diabetes Mellitus 1,Insulin-Dependent Diabetes Mellitus,Juvenile Onset Diabetes,Juvenile-Onset Diabetes Mellitus,Ketosis-Prone Diabetes Mellitus,Sudden-Onset Diabetes Mellitus
D005260 Female Females
D006442 Glycated Hemoglobin Products of non-enzymatic reactions between GLUCOSE and HEMOGLOBIN (occurring as a minor fraction of the hemoglobin of ERYTHROCYTES.) It generally refers to glycated HEMOGLOBIN A. Hemoglobin A1c (Hb A1c) is hemoglobin A with GLYCATION on a terminal VALINE of the beta chain. Glycated hemoglobin A is used as an index of the average blood sugar level over a lifetime of erythrocytes. Fructated Hemoglobins,Glycohemoglobin,Glycohemoglobin A,Glycohemoglobins,Glycosylated Hemoglobin A,Hb A1c,HbA1,Hemoglobin A(1),Hemoglobin A, Glycosylated,Glycated Hemoglobin A,Glycated Hemoglobin A1c,Glycated Hemoglobins,Glycosylated Hemoglobin A1c,Hb A1,Hb A1a+b,Hb A1a-1,Hb A1a-2,Hb A1b,Hemoglobin, Glycated A1a-2,Hemoglobin, Glycated A1b,Hemoglobin, Glycosylated,Hemoglobin, Glycosylated A1a-1,Hemoglobin, Glycosylated A1b,A1a-1 Hemoglobin, Glycosylated,A1a-2 Hemoglobin, Glycated,A1b Hemoglobin, Glycated,A1b Hemoglobin, Glycosylated,Glycated A1a-2 Hemoglobin,Glycated A1b Hemoglobin,Glycosylated A1a-1 Hemoglobin,Glycosylated A1b Hemoglobin,Glycosylated Hemoglobin,Hemoglobin A, Glycated,Hemoglobin A1c, Glycated,Hemoglobin A1c, Glycosylated,Hemoglobin, Glycated,Hemoglobin, Glycated A1a 2,Hemoglobin, Glycosylated A1a 1,Hemoglobins, Fructated,Hemoglobins, Glycated
D006650 Histocompatibility Testing Identification of the major histocompatibility antigens of transplant DONORS and potential recipients, usually by serological tests. Donor and recipient pairs should be of identical ABO blood group, and in addition should be matched as closely as possible for HISTOCOMPATIBILITY ANTIGENS in order to minimize the likelihood of allograft rejection. (King, Dictionary of Genetics, 4th ed) Crossmatching, Tissue,HLA Typing,Tissue Typing,Crossmatchings, Tissue,HLA Typings,Histocompatibility Testings,Testing, Histocompatibility,Testings, Histocompatibility,Tissue Crossmatching,Tissue Crossmatchings,Tissue Typings,Typing, HLA,Typing, Tissue,Typings, HLA,Typings, Tissue

Related Publications

P B Carroll, and P Fontes, and A S Rao, and C Ricordi, and H L Rilo, and A Zeevi, and M Trucco, and R Shapiro, and W B Rybka, and V Scantlebury
Islet allotransplantation in type 1 diabetic patients.
June 2003, Minerva endocrinologica,
P B Carroll, and P Fontes, and A S Rao, and C Ricordi, and H L Rilo, and A Zeevi, and M Trucco, and R Shapiro, and W B Rybka, and V Scantlebury
Results of human islet allotransplantation in cystic fibrosis and type I diabetic patients.
March 1998, Transplantation proceedings,
P B Carroll, and P Fontes, and A S Rao, and C Ricordi, and H L Rilo, and A Zeevi, and M Trucco, and R Shapiro, and W B Rybka, and V Scantlebury
Islet allotransplantation in type I diabetic patients: effects of islet cell number on clinical outcome.
October 1996, Transplantation proceedings,
P B Carroll, and P Fontes, and A S Rao, and C Ricordi, and H L Rilo, and A Zeevi, and M Trucco, and R Shapiro, and W B Rybka, and V Scantlebury
Bone marrow chimerism as a strategy to produce tolerance in solid organ allotransplantation.
December 2016, Current opinion in organ transplantation,
P B Carroll, and P Fontes, and A S Rao, and C Ricordi, and H L Rilo, and A Zeevi, and M Trucco, and R Shapiro, and W B Rybka, and V Scantlebury
Human islet allotransplantation with Basiliximab in type I diabetic patients with end-stage renal failure.
May 2002, Transplantation proceedings,
P B Carroll, and P Fontes, and A S Rao, and C Ricordi, and H L Rilo, and A Zeevi, and M Trucco, and R Shapiro, and W B Rybka, and V Scantlebury
Donor bone marrow infusions in conjunction with liver-islet allotransplantation in patients with type 2 diabetes.
January 1997, Transplantation proceedings,
P B Carroll, and P Fontes, and A S Rao, and C Ricordi, and H L Rilo, and A Zeevi, and M Trucco, and R Shapiro, and W B Rybka, and V Scantlebury
Islet Allotransplantation in the Bone Marrow of Patients With Type 1 Diabetes: A Pilot Randomized Trial.
April 2019, Transplantation,
P B Carroll, and P Fontes, and A S Rao, and C Ricordi, and H L Rilo, and A Zeevi, and M Trucco, and R Shapiro, and W B Rybka, and V Scantlebury
Human islet allotransplantation in 18 diabetic patients.
June 1992, Transplantation proceedings,
P B Carroll, and P Fontes, and A S Rao, and C Ricordi, and H L Rilo, and A Zeevi, and M Trucco, and R Shapiro, and W B Rybka, and V Scantlebury
Simultaneous islet liver allotransplantation in rats.
January 2002, Transplantation,
P B Carroll, and P Fontes, and A S Rao, and C Ricordi, and H L Rilo, and A Zeevi, and M Trucco, and R Shapiro, and W B Rybka, and V Scantlebury
Allotransplantation of fresh islets in four type I diabetic patients.
June 1992, Transplantation proceedings,
Copied contents to your clipboard!